Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05873686 · ClinicalTrials.gov registry record · Phase 1
A Phase 1 Clinical Study of NXP900 in Subjects With Advanced Cancers
A Phase 1 study of Advanced Solid Tumor and Mesothelioma, sponsored by Nuvectis Pharma.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 140
- Enrollment target
- 12
- Study locations
NCT05873686: Recruiting Phase 1 study of Advanced Solid Tumor and Mesothelioma, sponsored by Nuvectis Pharma.
NCT05873686 is a Phase 1 study of Advanced Solid Tumor and Mesothelioma that is actively recruiting participants, run by Nuvectis Pharma. The registered enrollment target is 140 participants, below the 192-participant average among 189 other Advanced Solid Tumor trials with a reported enrollment target (27% lower). The trial reports 12 study locations across 9 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05873686, a Phase 1 study of Advanced Solid Tumor and Mesothelioma, is actively recruiting participants, sponsored by Nuvectis Pharma.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 140 participants
- Enrollment target
- 12
- Study locations
Study Summary
This is a multi-center, first-in-human, open label, dose escalation (Part A) and expansion (Part B) Phase 1 study in subjects with advanced solid tumors and in subjects with solid tumors with selected genetic alterations that are either direct (YES1 amplification) or dependent (Hippo Pathway alterations) targets of NXP900.
Conditions Studied
Interventions
- DRUG NXP900
Study Locations (12)
Texas
- The University of Texas MD Anderson Cancer Center - Houston
- NEXT Oncology Houston - Houston
- NEXT Oncology Dallas - Irving
Other
- Western General Hospital - NHS Lothian - Edinburgh
- The Royal Marsden NHS Foundation and Trust - London
Arizona
- Mayo Clinic - Phoenix
Colorado
- Sarah Cannon Research Institute at HealthONE - Denver
Florida
- Mayo Clinic - Jacksonville
Illinois
- University of Chicago - Chicago
Minnesota
- Mayo Clinic Rochester - Rochester
Oregon
- Oregon Health and Science University - Portland
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 140 participants |
| Start Date | 2023-10-26 |
| Est. Completion | 2027-07 |
| Phase | Phase 1 |
What NCT05873686 shows while recruiting
NCT05873686 is an interventional study that assigns participants to a tested intervention. The registered 140 participants enrollment target is mid-sized for trials with a published cap, below the 192-participant average among 189 other Advanced Solid Tumor trials with a reported enrollment target (27% lower).
The record links to 6 conditions, with Advanced Solid Tumor appearing as the primary indexed condition, and to 1 intervention - of which NXP900 is the first listed.
NCT05873686 lists 12 locations in 9 states (Texas, Other, Arizona).
Frequently Asked Questions
What is clinical trial NCT05873686 about?
NCT05873686 is a clinical study titled "A Phase 1 Clinical Study of NXP900 in Subjects With Advanced Cancers". This is a multi-center, first-in-human, open label, dose escalation (Part A) and expansion (Part B) Phase 1 study in subjects with advanced solid tumors and in subjects with solid tumors with selected genetic alterations that are either direct (YES1 amplification) or dependent (Hippo Pathway alterat...
What is the current status of trial NCT05873686?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 140 participants. The study started on 2023-10-26. Estimated completion is 2027-07.
What conditions does trial NCT05873686 study?
This clinical trial studies the following conditions: Advanced Solid Tumor, Mesothelioma, Renal Cancer, NSCLC (Non-small Cell Lung Cancer), Non-Small Cell Squamous Lung Cancer.
What interventions are being tested in trial NCT05873686?
The interventions under investigation include: NXP900 (DRUG).
Who is sponsoring clinical trial NCT05873686?
This trial is sponsored by Nuvectis Pharma, which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05873686 being conducted?
This trial has 12 study locations across Arizona, Colorado, Florida, Illinois, Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Advanced Solid Tumor
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05873686's enrollment target sits among peer trials
140 96th of 189 higher than 94 of 189 other Advanced Solid Tumor trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Advanced Solid Tumor trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
PM14 Administered Intravenously to Patients with Advanced Solid Tumors
RECRUITING · Phase 1
-
A Study of EP0031 in Patients With Advanced RET-altered Malignancies
RECRUITING · Phase 1
-
Study of AVZO-021 in Patients With Advanced Solid Tumors
RECRUITING · Phase 1
-
A First-in-Human Study of YL217 in Patients With Advanced Solid Tumors
RECRUITING · Phase 1
-
Study of Orally Administered MOMA-313 in Participants With Advanced or Metastatic Solid Tumors
RECRUITING · Phase 1
-
Phase I Study of Tolododekin Alfa (ANK-101) in Advanced Solid Tumors
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01419561 · 140 participants · Phase 2
Natural History Study of the KSHV Inflammatory Cytokine Syndrome (KICS)
- NCT01624805 · 140 participants · Phase 2
Methylprednisolone, Horse Anti-Thymocyte Globulin, Cyclosporine, Filgrastim, and/or Pegfilgrastim or Pegfilgrastim Biosimilar in Treating Patients With Aplastic Anemia or Low or Intermediate-Risk Myelodysplastic Syndrome
- NCT02369770 · 140 participants · NA
Sensory-Motor Rehabilitation Post Stroke
- NCT02455193 · 140 participants · NA
Neuronal Effects of Exercise in Schizophrenia
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI